TRDA (entradatx.com) יחס שווי שוק לשווי בספרים

The success of Entrada Therapeutics (TRDA) therapy relies on the flawless precision of drug delivery into cells. The share price retrospective on the GURU.Markets platform reflects the asset's dynamics, where the current figure is 0.73. This is driven by a lack of internal revenue and the consumption of capital for R&D, as well as the complete outsourcing of synthesis and testing to third-party contractors (CRO/CMO), which creates a high dependency on vendors.

The market-to-book ratio measures the premium or discount of a business's value relative to its net assets, as reflected in the history of the market capitalization to book value ratio. The current level of 0.73 demonstrates the market valuation of the intellectual capital of Entrada Therapeutics (TRDA), where its proprietary drug delivery platform minimizes competitive risks and justifies a company valuation above its nominal capital.